Delivery Order SPE2DB24D2215-SPE2DB25FGSWB
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,808.31 for ACTEMRA ACTPEN 162 MG/0.9 ML (tocilizumab auto-injector pens), a biologic immunosuppressant medication used to treat rheumatoid arthritis and other inflammatory conditions. The contract was competitively awarded without a set-aside designation and is structured as a firm fixed price delivery order with an ultimate completion date of October 21, 2025. Performance will take place at...
- The Defense Logistics Agency awarded a delivery order valued at $5,755.68 to AmerisourceBergen Drug Corp for ACTEMRA ACTPEN 162 MG/0.9 ML auto-injectors. This non-set-aside, firm fixed price delivery order was awarded on July 22, 2025, with an ultimate completion date of July 23, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. ACTEMRA (tocilizumab) is a biologic immunosuppressant used to treat rheumatoid arthritis and other...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,791.56 for ACTEMRA ACTPEN 162 mg/0.9 mL auto-injector pens on August 11, 2025, with performance completion scheduled for August 12, 2025. This firm fixed price delivery order represents a non-set-aside, competitively awarded contract with no small business or other socioeconomic preferences applied. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.88 to AmerisourceBergen Drug Corp for the supply of Actemra Actpen 162 mg/0.9 ml auto-injectors. This firm fixed-price, non-set-aside contract was awarded on September 9, 2025, with an ultimate completion date of September 10, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Actemra (tocilizumab) is a biologic immunosuppressant used to treat rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,382.29 to AmerisourceBergen Drug Corp for Actemra ActPen (tocilizumab) 162 mg/0.9 mL auto-injectors. This firm fixed-price delivery order, issued on November 7, 2025, with completion targeted for November 10, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The product will be...
- The Defense Logistics Agency awarded a $13,292.11 delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of Actemra (tocilizumab) Actpen 162 mg/0.9 mL auto-injectors. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's facility...
- The Defense Logistics Agency awarded a delivery order valued at $1,715.91 to AmerisourceBergen Drug Corp for ACTEMRA ACTPEN 162 MG/0.9 ML (tocilizumab auto-injector) on November 7, 2025, with completion scheduled for November 10, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, one of the nation's largest...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,877.84 to AmerisourceBergen Drug Corp for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. This firm fixed-price contract was competitively awarded without set-asides and is scheduled for completion by June 20, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $49,591.32 delivery order to AmerisourceBergen Drug Corp for the supply of Actemra Actpen (tocilizumab) 162 mg/0.9 mL auto-injector pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with performance to be completed by September 29, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Actemra ActPen (162 mg/0.9 mL) auto-injectors. This firm fixed price delivery order carries a ceiling value of $3,066.26 and is scheduled for completion by August 19, 2025. The contract was competitively awarded without set-aside provisions, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements....
- SPE2DB24D2215Indefinite Delivery Contract
- SPE2DB24D2215-SPE2DB25FGSWBDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,219.45 to AmerisourceBergen Drug Corp for ACTEMRA ACTPEN 162 mg/0.9 mL auto-injector pens. The contract was competitively awarded without set-aside provisions on May 13, 2025, with an ultimate completion date of May 14, 2025. This delivery order operates under a firm fixed-price arrangement and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. ACTEMRA (tocilizumab) is a biologic immunosuppressant medication commonly used in military and federal healthcare systems for treating rheumatoid arthritis and other inflammatory conditions. This delivery order is a child contract issued under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This IDC serves as the primary pharmaceutical supply vehicle for the Defense Health Agency and other federal healthcare systems, enabling flexible procurement of a comprehensive range of brand-name and generic medications, biologics, and medical supplies to support military healthcare operations globally. AmerisourceBergen's position as a pharmaceutical prime vendor reflects its critical role in the federal medical supply chain, delivering specialized and routine pharmaceutical products across multiple therapeutic domains to support military readiness and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 5/13/25 |